Envoy Medical reports that all 56 participants in its pivotal Acclaim cochlear implant trial have been activated, marking progress beyond initial milestones as the team moves toward collecting follow-up data. The company has already surpassed the three‑month visit milestone and expects six‑month data by late 2026, with full 12‑month results anticipated by April 2027, setting up a PMA submission timeline to the FDA. Management emphasizes that activation demonstrates device use, while the critical test now will be the quality and safety of the outcome data over the follow‑up period. In ongoing results, the 12‑month data show a notable mean consonant-nucleus-consonant word recognition score improvement to 53.2% from 15.2% pre‑implantation, reflecting substantial functional gains. While the milestones illustrate strong execution and regulatory momentum, Envoy Medical cautions that PMA submission does not equal approval, as the FDA review remains in its early stages. Both press releases cite similar milestones and forward‑looking goals, underscoring a concerted push toward bringing a fully implanted cochlear implant to market in the United States.